Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 417

1.

Vitamin D status and non-alcoholic fatty liver disease in patients with type 1 diabetes.

Cipponeri E, Vitturi N, Mariano V, Boscari F, Galasso S, Crepaldi C, Fadini GP, Vigili de Kreutzenberg S, Marescotti MC, Iori E, Cavallin F, Sartori L, Baritussio A, Avogaro A, Bruttomesso D.

J Endocrinol Invest. 2019 Mar 7. doi: 10.1007/s40618-019-01031-8. [Epub ahead of print]

PMID:
30847862
2.

Microvascular complications in diabetes: A growing concern for cardiologists.

Avogaro A, Fadini GP.

Int J Cardiol. 2019 Feb 25. pii: S0167-5273(18)36875-X. doi: 10.1016/j.ijcard.2019.02.030. [Epub ahead of print] Review.

PMID:
30833106
3.

Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus.

Sesti G, Avogaro A, Belcastro S, Bonora BM, Croci M, Daniele G, Dauriz M, Dotta F, Formichi C, Frontoni S, Invitti C, Orsi E, Picconi F, Resi V, Bonora E, Purrello F.

Acta Diabetol. 2019 Jan 2. doi: 10.1007/s00592-018-1271-3. [Epub ahead of print] Review.

PMID:
30603867
4.

Comparative effectiveness of exenatide once-weekly versus liraglutide in routine clinical practice: A retrospective multicentre study and meta-analysis of observational studies.

Fadini GP, Bonora BM, Lapolla A, Fattor B, Morpurgo PS, Simioni N, Avogaro A; DARWIN-T2D Network.

Diabetes Obes Metab. 2018 Dec 21. doi: 10.1111/dom.13623. [Epub ahead of print]

PMID:
30578607
5.

Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study.

Fadini GP, Solini A, Manca ML, Penno G, Gatti A, Anichini R, Del Prato S, Avogaro A; DARWIN-T2D Network.

Diabetes Obes Metab. 2019 Feb;21(2):252-260. doi: 10.1111/dom.13508. Epub 2018 Sep 21.

PMID:
30136354
6.

Impaired cognitive processing speed in type 1 diabetic patients who had severe/recurrent hypoglycaemia.

Bortolotti S, Zarantonello L, Uliana A, Vitturi N, Schiff S, Bisiacchi P, Avogaro A, Amodio P, Maran A.

J Diabetes Complications. 2018 Nov;32(11):1040-1045. doi: 10.1016/j.jdiacomp.2018.08.005. Epub 2018 Aug 10.

PMID:
30121207
7.

Effects of SGLT2 Inhibitors on Circulating Stem and Progenitor Cells in Patients With Type 2 Diabetes.

Bonora BM, Cappellari R, Albiero M, Avogaro A, Fadini GP.

J Clin Endocrinol Metab. 2018 Oct 1;103(10):3773-3782. doi: 10.1210/jc.2018-00824.

PMID:
30113651
8.

Phenotyping normal kidney function in elderly patients with type 2 diabetes: a cross-sectional multicentre study.

Fadini GP, Solini A, Manca ML, Zatti G, Karamouzis I, Di Benedetto A, Frittitta L, Avogaro A; DARWIN-T2D Network.

Acta Diabetol. 2018 Nov;55(11):1121-1129. doi: 10.1007/s00592-018-1194-z. Epub 2018 Aug 9.

PMID:
30090961
9.

Exposure to insulin degludec during pregnancy: report of a small series and review of the literature.

Bonora BM, Avogaro A, Fadini GP.

J Endocrinol Invest. 2019 Mar;42(3):345-349. doi: 10.1007/s40618-018-0926-9. Epub 2018 Jul 24.

PMID:
30043095
10.

Comparative Effectiveness of DPP-4 Inhibitors Versus Sulfonylurea for the Treatment of Type 2 Diabetes in Routine Clinical Practice: A Retrospective Multicenter Real-World Study.

Fadini GP, Bottigliengo D, D'Angelo F, Cavalot F, Bossi AC, Zatti G, Baldi I, Avogaro A; DARWIN-T2D Network.

Diabetes Ther. 2018 Aug;9(4):1477-1490. doi: 10.1007/s13300-018-0452-y. Epub 2018 Jun 1.

11.

Characteristics, prevalence, and outcomes of diabetic foot ulcers in Africa. A systemic review and meta-analysis.

Rigato M, Pizzol D, Tiago A, Putoto G, Avogaro A, Fadini GP.

Diabetes Res Clin Pract. 2018 Aug;142:63-73. doi: 10.1016/j.diabres.2018.05.016. Epub 2018 May 26. Review.

PMID:
29807105
12.

Diabetic retinopathy is associated with the presence and burden of subclinical carotid atherosclerosis in type 1 diabetes.

Carbonell M, Castelblanco E, Valldeperas X, Betriu À, Traveset A, Granado-Casas M, Hernández M, Vázquez F, Martín M, Rubinat E, Lecube A, Franch-Nadal J, Fernández E, Puig-Domingo M, Avogaro A, Alonso N, Mauricio D.

Cardiovasc Diabetol. 2018 May 4;17(1):66. doi: 10.1186/s12933-018-0706-z.

13.

The pleiotropic cardiovascular effects of dipeptidyl peptidase-4 inhibitors.

Avogaro A, Fadini GP.

Br J Clin Pharmacol. 2018 Aug;84(8):1686-1695. doi: 10.1111/bcp.13611. Epub 2018 Jun 3. Review.

PMID:
29667232
14.

Pharmacovigilance Evaluation of the Association Between DPP-4 Inhibitors and Heart Failure: Stimulated Reporting and Moderation by Drug Interactions.

Fadini GP, Sarangdhar M, Avogaro A.

Diabetes Ther. 2018 Apr;9(2):851-861. doi: 10.1007/s13300-018-0408-2. Epub 2018 Mar 16.

15.

The antidiabetic drug metformin blunts NETosis in vitro and reduces circulating NETosis biomarkers in vivo.

Menegazzo L, Scattolini V, Cappellari R, Bonora BM, Albiero M, Bortolozzi M, Romanato F, Ceolotto G, Vigili de Kreutzeberg S, Avogaro A, Fadini GP.

Acta Diabetol. 2018 Jun;55(6):593-601. doi: 10.1007/s00592-018-1129-8. Epub 2018 Mar 15.

PMID:
29546579
16.

Insulin treatment in patients with diabetes and heart failure: defendant on the stand.

Avogaro A, Fadini GP.

Eur J Heart Fail. 2018 May;20(5):896-897. doi: 10.1002/ejhf.1161. Epub 2018 Mar 8. No abstract available.

PMID:
29517118
17.

Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study.

Fadini GP, Zatti G, Baldi I, Bottigliengo D, Consoli A, Giaccari A, Sesti G, Avogaro A; DARWIN-T2D network.

Diabetes Obes Metab. 2018 Jul;20(7):1781-1786. doi: 10.1111/dom.13280. Epub 2018 Mar 30.

18.

Head-to-head comparison of the accuracy of Abbott FreeStyle Libre and Dexcom G5 mobile.

Boscari F, Galasso S, Acciaroli G, Facchinetti A, Marescotti MC, Avogaro A, Bruttomesso D.

Nutr Metab Cardiovasc Dis. 2018 Apr;28(4):425-427. doi: 10.1016/j.numecd.2018.01.003. Epub 2018 Jan 31. No abstract available.

PMID:
29502924
19.

Interplay between gut microbiota and p66Shc affects obesity-associated insulin resistance.

Ciciliot S, Albiero M, Campanaro S, Poncina N, Tedesco S, Scattolini V, Dalla Costa F, Cignarella A, Vettore M, Di Gangi IM, Bogialli S, Avogaro A, Fadini GP.

FASEB J. 2018 Jul;32(7):4004-4015. doi: 10.1096/fj.201701409R. Epub 2018 Feb 21.

PMID:
29466053
20.

Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System.

Fadini GP, Sarangdhar M, Avogaro A.

BMJ Open Diabetes Res Care. 2018 Jan 30;6(1):e000475. doi: 10.1136/bmjdrc-2017-000475. eCollection 2018.

21.

Systemic and vascular inflammation in an in-vitro model of central obesity.

Ahluwalia A, Misto A, Vozzi F, Magliaro C, Mattei G, Marescotti MC, Avogaro A, Iori E.

PLoS One. 2018 Feb 13;13(2):e0192824. doi: 10.1371/journal.pone.0192824. eCollection 2018.

22.

How to interpret the role of SDF-1α on diabetic complications during therapy with DPP-4 inhibitors.

Fadini GP, Avogaro A.

Cardiovasc Diabetol. 2018 Feb 2;17(1):22. doi: 10.1186/s12933-018-0668-1. No abstract available.

23.

Counterpoint to the hypothesis that SGLT2 inhibitors protect the heart by antagonizing leptin.

Avogaro A, Fadini GP.

Diabetes Obes Metab. 2018 Jun;20(6):1367-1368. doi: 10.1111/dom.13234. Epub 2018 Feb 21. No abstract available.

PMID:
29377537
24.

p66Shc gene expression in peripheral blood mononuclear cells and progression of diabetic complications.

Fadini GP, Albiero M, Bonora BM, Poncina N, Vigili de Kreutzenberg S, Avogaro A.

Cardiovasc Diabetol. 2018 Jan 17;17(1):16. doi: 10.1186/s12933-018-0660-9.

25.

When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy.

Avogaro A, Delgado E, Lingvay I.

Diabetes Metab Res Rev. 2018 May;34(4):e2981. doi: 10.1002/dmrr.2981. Epub 2018 Feb 15. Review.

PMID:
29320602
26.

Effects of Hypoglycemia on Circulating Stem and Progenitor Cells in Diabetic Patients.

Fadini GP, Boscari F, Cappellari R, Galasso S, Rigato M, Bonora BM, D'Anna M, Bruttomesso D, Avogaro A.

J Clin Endocrinol Metab. 2018 Mar 1;103(3):1048-1055. doi: 10.1210/jc.2017-02187.

PMID:
29300991
27.

Assessment of hypoglycaemia during basal insulin therapy: Temporal distribution and risk of events using a predefined or an expanded definition of nocturnal events.

Riddle MC, Bolli GB, Avogaro A, Gimenez Álvarez M, Merino-Trigo A, Boëlle-Le Corfec E, Home PD.

Diabetes Metab. 2018 Sep;44(4):333-340. doi: 10.1016/j.diabet.2017.12.001. Epub 2017 Dec 11.

28.

FreeStyle Libre and Dexcom G4 Platinum sensors: Accuracy comparisons during two weeks of home use and use during experimentally induced glucose excursions.

Boscari F, Galasso S, Facchinetti A, Marescotti MC, Vallone V, Amato AML, Avogaro A, Bruttomesso D.

Nutr Metab Cardiovasc Dis. 2018 Feb;28(2):180-186. doi: 10.1016/j.numecd.2017.10.023. Epub 2017 Nov 11.

PMID:
29258716
29.

Keeping the right track in the treatment of patients with type 2 diabetes.

Avogaro A.

Eur J Heart Fail. 2018 Jan;20(1):52-54. doi: 10.1002/ejhf.1118. Epub 2017 Dec 18. No abstract available.

30.

Factors that may Account for Cardiovascular Risk Reduction with a Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, in Young Patients with Type 2 Diabetes Mellitus.

Evans M, Kozlovski P, Paldánius PM, Foley JE, Bhosekar V, Serban C, Avogaro A.

Diabetes Ther. 2018 Feb;9(1):27-36. doi: 10.1007/s13300-017-0329-5. Epub 2017 Nov 13.

31.

Dipeptidyl peptidase-4 inhibitors moderate the risk of genitourinary tract infections associated with sodium-glucose co-transporter-2 inhibitors.

Fadini GP, Bonora BM, Mayur S, Rigato M, Avogaro A.

Diabetes Obes Metab. 2018 Mar;20(3):740-744. doi: 10.1111/dom.13130. Epub 2017 Nov 15.

PMID:
29053207
32.

Shift of monocyte subsets along their continuum predicts cardiovascular outcomes.

Cappellari R, D'Anna M, Bonora BM, Rigato M, Cignarella A, Avogaro A, Fadini GP.

Atherosclerosis. 2017 Nov;266:95-102. doi: 10.1016/j.atherosclerosis.2017.09.032. Epub 2017 Sep 29.

PMID:
29017104
33.

miR-30c-5p regulates macrophage-mediated inflammation and pro-atherosclerosis pathways.

Ceolotto G, Giannella A, Albiero M, Kuppusamy M, Radu C, Simioni P, Garlaschelli K, Baragetti A, Catapano AL, Iori E, Fadini GP, Avogaro A, Vigili de Kreutzenberg S.

Cardiovasc Res. 2017 Nov 1;113(13):1627-1638. doi: 10.1093/cvr/cvx157.

PMID:
29016810
34.

Rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes): A multicenter retrospective nationwide Italian study and crowdsourcing opportunity.

Fadini GP, Zatti G, Consoli A, Bonora E, Sesti G, Avogaro A; DARWIN-T2D Network.

Nutr Metab Cardiovasc Dis. 2017 Dec;27(12):1089-1097. doi: 10.1016/j.numecd.2017.08.001. Epub 2017 Aug 8.

PMID:
28967594
35.

Circulating levels and characterization of microparticles in patients with different degrees of glucose tolerance.

Giannella A, Radu CM, Franco L, Campello E, Simioni P, Avogaro A, de Kreutzenberg SV, Ceolotto G.

Cardiovasc Diabetol. 2017 Sep 19;16(1):118. doi: 10.1186/s12933-017-0600-0.

36.

Comparison of lower limb muscle strength between diabetic neuropathic and healthy subjects using OpenSim.

Scarton A, Jonkers I, Guiotto A, Spolaor F, Guarneri G, Avogaro A, Cobelli C, Sawacha Z.

Gait Posture. 2017 Oct;58:194-200. doi: 10.1016/j.gaitpost.2017.07.117. Epub 2017 Jul 31.

PMID:
28802220
37.

SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System.

Fadini GP, Avogaro A.

Lancet Diabetes Endocrinol. 2017 Sep;5(9):680-681. doi: 10.1016/S2213-8587(17)30257-7. Epub 2017 Jul 18. No abstract available. Erratum in: Lancet Diabetes Endocrinol. 2018 Apr 13;:.

PMID:
28733172
38.

Overnight Closed-Loop Control Improves Glycemic Control in a Multicenter Study of Adults With Type 1 Diabetes.

Brown SA, Breton MD, Anderson SM, Kollar L, Keith-Hynes P, Levy CJ, Lam DW, Levister C, Baysal N, Kudva YC, Basu A, Dadlani V, Hinshaw L, McCrady-Spitzer S, Bruttomesso D, Visentin R, Galasso S, Del Favero S, Leal Y, Boscari F, Avogaro A, Cobelli C, Kovatchev BP.

J Clin Endocrinol Metab. 2017 Oct 1;102(10):3674-3682. doi: 10.1210/jc.2017-00556.

39.

Re: "Plasminogen Activator Inhibitor-1 and Pericardial Fat in Individuals with Type 2 Diabetes Mellitus" by Bayomi et al. (Metab Syndr Relat Disord 2017;15:269-275).

Avogaro A.

Metab Syndr Relat Disord. 2017 Aug;15(6):266-268. doi: 10.1089/met.2017.0070. Epub 2017 Jun 12.

PMID:
28605281
40.

Cognitive, neurophysiologic and metabolic sequelae of previous hypoglycemic coma revealed by hyperinsulinemic-hypoglycemic clamp in type 1 diabetic patients.

Maran A, Crepaldi C, Del Piccolo F, Macdonald I, Zarantonello L, Avogaro A, Amodio P.

Metab Brain Dis. 2017 Oct;32(5):1543-1551. doi: 10.1007/s11011-017-0041-1. Epub 2017 Jun 6.

PMID:
28589447
41.

A decade-long telemedicine screening program for diabetic retinopathy in the north-east of Italy.

Vujosevic S, Pucci P, Casciano M, Daniele A, Bini S, Berton M, Cavarzeran F, Avogaro A, Lapolla A, Midena E.

J Diabetes Complications. 2017 Aug;31(8):1348-1353. doi: 10.1016/j.jdiacomp.2017.04.010. Epub 2017 Apr 13.

PMID:
28551296
42.

Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature.

Bonora BM, Avogaro A, Fadini GP.

Diabetes Obes Metab. 2018 Jan;20(1):25-33. doi: 10.1111/dom.13012. Epub 2017 Jul 6. Review.

PMID:
28517913
43.

SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System.

Fadini GP, Bonora BM, Avogaro A.

Diabetologia. 2017 Aug;60(8):1385-1389. doi: 10.1007/s00125-017-4301-8. Epub 2017 May 12.

PMID:
28500396
44.

Intraclass differences in the risk of hospitalization for heart failure among patients with type 2 diabetes initiating a dipeptidyl peptidase-4 inhibitor or a sulphonylurea: Results from the OsMed Health-DB registry.

Fadini GP, Saragoni S, Russo P, Degli Esposti L, Vigili de Kreutzenberg S, Melazzini M, Avogaro A; OsMed Health DB Network.

Diabetes Obes Metab. 2017 Oct;19(10):1416-1424. doi: 10.1111/dom.12979. Epub 2017 May 31.

PMID:
28432754
45.

A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus.

Avogaro A, Giaccari A, Fioretto P, Genovese S, Purrello F, Giorgino F, Del Prato S.

Expert Rev Clin Pharmacol. 2017 Jul;10(7):763-772. doi: 10.1080/17512433.2017.1322507. Epub 2017 May 2. Review.

PMID:
28431476
46.

Silent coronary heart disease in patients with type 2 diabetes: application of a screening approach in a follow-up study.

Vigili de Kreutzenberg S, Solini A, Vitolo E, Boi A, Bacci S, Cocozza S, Nappo R, Rivellese A, Avogaro A, Baroni MG.

J Diabetes Complications. 2017 Jun;31(6):952-957. doi: 10.1016/j.jdiacomp.2017.03.014. Epub 2017 Apr 4.

PMID:
28416121
47.

Mechanisms linking empagliflozin to cardiovascular and renal protection.

Perrone-Filardi P, Avogaro A, Bonora E, Colivicchi F, Fioretto P, Maggioni AP, Sesti G, Ferrannini E.

Int J Cardiol. 2017 Aug 15;241:450-456. doi: 10.1016/j.ijcard.2017.03.089. Epub 2017 Mar 23. Review.

PMID:
28395981
48.

Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial.

Fadini GP, Bonora BM, Zatti G, Vitturi N, Iori E, Marescotti MC, Albiero M, Avogaro A.

Cardiovasc Diabetol. 2017 Apr 4;16(1):42. doi: 10.1186/s12933-017-0529-3.

49.

Persistent Reduction of Circulating Myeloid Calcifying Cells in Acromegaly: Relevance to the Bone-Vascular Axis.

Fadini GP, Dassie F, Cappellari R, Persano M, Vigili de Kreutzenberg S, Martini C, Parolin M, Avogaro A, Vettor R, Maffei P.

J Clin Endocrinol Metab. 2017 Jun 1;102(6):2044-2050. doi: 10.1210/jc.2017-00246.

PMID:
28323966
50.

Reduced circulating stem cells associate with excess fasting and post-load NEFA exposure in healthy adults with normal glucose tolerance.

Fadini GP, Tura A, Pacini G, Avogaro A, Vigili de Kreutzenberg S.

Atherosclerosis. 2017 Jun;261:117-123. doi: 10.1016/j.atherosclerosis.2017.03.002. Epub 2017 Mar 6.

PMID:
28298252

Supplemental Content

Loading ...
Support Center